GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

Quarterly revenues increased 10% on a reported basis and 13% at CER to $9.95 billion (£7.88 billion), beating the Zacks Consensus Estimate of $9.49 billion. The upside can be attributed to rising HIV and respiratory product sales, partially offset by the declining COVID-19 product sales. HIV sales rose 13%, driven by sales of new HIV drugs — Juluca, Dovato, Cabenuva and Apretude. Sales of the respiratory drug Nucala were up 17% during the quarter, driven by growth across the markets. General Medicines sales ...